Universal Diagnostics SL (Universal DX) is a biomedicine company that develops blood-based screening tests for the early detection of cancer. The company's product include Signal-C, a blood-based colorectal cancer screening test designed to detect colorectal cancer and pre-cancerous lesions. It offers clinical trials. UDX's products are used in the healthcare industry in cancer detection and prevention. The company collaborates with technological and medical institutions. It partners with several biobanks and hospitals. Universal DX is headquartered in Sevilla, Spain.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Universal Diagnostics SL
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design, trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company
Table of Contents
- Universal Diagnostics SL Company Overview
- Universal Diagnostics SL Company Snapshot
- Universal Diagnostics SL Pipeline Products and Ongoing Clinical Trials Overview
- Universal Diagnostics SL - Pipeline Analysis Overview
- Universal Diagnostics SL - Key Facts
- Universal Diagnostics SL - Major Products and Services
- Universal Diagnostics SL Pipeline Products by Development Stage
- Universal Diagnostics SL Ongoing Clinical Trials by Trial Status
- Universal Diagnostics SL Pipeline Products Overview
- Blood-Based Diagnostic Test - Breast Cancer
- Blood-Based Diagnostic Test - Breast Cancer Product Overview
- Blood-Based Diagnostic Test - Colorectal Cancer
- Blood-Based Diagnostic Test - Colorectal Cancer Product Overview
- Multi-Cancer Detection Test
- Multi-Cancer Detection Test Product Overview
- Signal LU
- Signal LU Product Overview
- Signal-C
- Signal-C Product Overview
- Signal-C Clinical Trial
- Signal-G
- Signal-G Product Overview
- Signal-L
- Signal-L Product Overview
- Signal-P
- Signal-P Product Overview
- Signal-X
- Signal-X Product Overview
- Universal Diagnostics SL - Key Competitors
- Universal Diagnostics SL - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Recent Developments
- Universal Diagnostics SL, Recent Developments
- Aug 15, 2024: Universal DX Initiates Clinical Trial for FDA Approval of Signal-C Colorectal Cancer Screening Blood Test
- Nov 20, 2023: Universal Dx Announces Strategic Collaboration With Quest Diagnostics To Bring Advanced Colorectal Cancer Screening Blood Test to Patients and Providers in the United States
- Nov 17, 2022: Universal DX presents methylation biomarker data at AACR special conference: precision prevention, early detection, and interception of cancer
- Sep 12, 2022: New findings from Universal DX: Through a simple blood test, our body’s gut bacteria can help detect early-stage colorectal cancer
- Jun 10, 2021: Universal DX presents data at EACR Virtual Congress; Top-Scoring poster shows accurate detection of colorectal advanced adenomas
- Jun 03, 2021: Cancer prevention and early detection are one step closer as Universal DX announces breakthrough study results from its Multi-Omics + Computational Biology + ML Blood test
- Mar 23, 2021: Universal Diagnostics initiates observational study in the US to evaluate cell free DNA blood test for adenomas and colorectal cancer
- Jan 28, 2021: Universal Diagnostics presents promising data on lung cancer detection using blood-based methylation test at the IASLC 2020 World Conference on Lung Cancer
- Sep 21, 2020: Universal Diagnostics presents new promising data on early (Pre) cancer detection from cell free DNA at European Society for Medical Oncology (ESMO)
- Nov 20, 2017: Universal Diagnostics Starts Clinical Study of Novel Blood Screening Test for Early Detection of Colon Cancer with Imperial College Healthcare NHS Trust
- Appendix
- Methodology
- About the Analyst
- Contact the Publisher
- Disclaimer
- Universal Diagnostics SL Pipeline Products and Ongoing Clinical Trials Overview
- Universal Diagnostics SL Pipeline Products by Equipment Type
- Universal Diagnostics SL Pipeline Products by Indication
- Universal Diagnostics SL Ongoing Clinical Trials by Trial Status
- Universal Diagnostics SL, Key Facts
- Universal Diagnostics SL, Major Products and Services
- Universal Diagnostics SL Number of Pipeline Products by Development Stage
- Universal Diagnostics SL Pipeline Products Summary by Development Stage
- Universal Diagnostics SL Ongoing Clinical Trials by Trial Status
- Universal Diagnostics SL Ongoing Clinical Trials Summary
- Blood-Based Diagnostic Test - Breast Cancer - Product Status
- Blood-Based Diagnostic Test - Breast Cancer - Product Description
- Blood-Based Diagnostic Test - Colorectal Cancer - Product Status
- Blood-Based Diagnostic Test - Colorectal Cancer - Product Description
- Multi-Cancer Detection Test - Product Status
- Multi-Cancer Detection Test - Product Description
- Signal LU - Product Status
- Signal LU - Product Description
- Signal-C - Product Status
- Signal-C - Product Description
- Signal-C - A Prospective, Multi-center, Observational Study for Signal-C Test Evaluation
- Signal-C - Collection of Samples from the United States Population for Optimization and Evaluation of Colorectal Cancer (CRC) Plasma Circulating Free-DNA (cfDNA) Marker Panel Performance ("USOPTIVAL")
- Signal-G - Product Status
- Signal-G - Product Description
- Signal-L - Product Status
- Signal-L - Product Description
- Signal-P - Product Status
- Signal-P - Product Description
- Signal-X - Product Status
- Signal-X - Product Description
- Universal Diagnostics SL, Other Locations
- Glossary
- Universal Diagnostics SL Pipeline Products by Equipment Type
- Universal Diagnostics SL Pipeline Products by Development Stage
- Universal Diagnostics SL Ongoing Clinical Trials by Trial Status
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Biokit SA
- Bioftalmik
- Biomedal SL
